This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Revance Therapeutics (RVNC) delivered earnings and revenue surprises of -5.71% and 11.60%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcellx (ACLX) delivered earnings and revenue surprises of 11.11% and 26.06%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Is Inspire Small/Mid Cap ETF (ISMD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for ISMD
Down -17.96% in 4 Weeks, Here's Why Revance Therapeutics (RVNC) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Revance Therapeutics (RVNC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
How Much Upside is Left in Revance Therapeutics (RVNC)? Wall Street Analysts Think 55.02%
by Zacks Equity Research
The consensus price target hints at a 55% upside potential for Revance Therapeutics (RVNC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Can Revance Therapeutics (RVNC) Climb 98.64% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 98.6% in Revance Therapeutics (RVNC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Revance Therapeutics (RVNC) delivered earnings and revenue surprises of 25% and 1.10%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Revance Therapeutics (RVNC) Loses -18.85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Revance Therapeutics (RVNC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Revance Therapeutics (RVNC) delivered earnings and revenue surprises of 18.18% and 6.66%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Krystal Biotech, Inc. (KRYS) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Krystal Biotech (KRYS) delivered earnings and revenue surprises of -85% and 0.57%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 28.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Qiagen (QGEN) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 4.55% and 0.73%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 0% and 5.76%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics (HALO) Q4 Earnings Match Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 0% and 2.22%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Revance Therapeutics, Inc. (RVNC) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Revance Therapeutics, Inc. (RVNC) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -11.11% and 0.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of -3.57% and 6.79%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
After Plunging -17.93% in 4 Weeks, Here's Why the Trend Might Reverse for Revance Therapeutics, Inc. (RVNC)
by Zacks Equity Research
Revance Therapeutics, Inc. (RVNC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Reata Pharmaceuticals, Inc. (RETA) Moves 7.0% Higher: Will This Strength Last?
by Zacks Equity Research
Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 1.33% and 8.53%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Top 4 Stocks Set to Beat on Earnings Today After Market Closes
by Nalak Das
We have narrowed our search to four stocks that are set to report earnings results today after market closes. These are: WYNN, CELH, RVNC and IAC.
Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Omega Therapeutics, Inc. (OMGA) delivered earnings and revenue surprises of 21.88% and 31.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Revance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intra-Cellular (ITCI) Surges 16.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Revance Therapeutics, Inc. (RVNC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -75% and 6.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?